{"id":525,"date":"2025-09-25T15:44:42","date_gmt":"2025-09-25T15:44:42","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/09\/25\/hsct-is-more-effective-than-anti-cd20-in-the-real-world\/"},"modified":"2025-09-25T15:44:42","modified_gmt":"2025-09-25T15:44:42","slug":"hsct-is-more-effective-than-anti-cd20-in-the-real-world","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/09\/25\/hsct-is-more-effective-than-anti-cd20-in-the-real-world\/","title":{"rendered":"HSCT is more effective than anti-CD20 in the real World"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2025%2F09%2Fhsct-is-more-effective-than-anti-cd20-in-the-real-world%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>Abit of a NSS momentpeople with this HSCT had few relapses but more inections that anti-CD20.<\/p>\n<p>Abstract Number: 1586\/P848 Effectiveness of autologous haematopoietic stem cell transplant in comparison with anti-CD20 therapies in relapsing-remitting multiple sclerosis <\/p>\n<p>Tomas Kalincik  et al.<\/p>\n<p>Introduction: Autologous hematopoietic stem cell transplant (AHSCT) is a potent therapy available to patients with suboptimal response to high-efficacy immunotherapy such as anti-CD20 antibodies. A sufficiently powered headto-head comparison of these two therapies is needed. Objectives\/Aims: Objectives\/Aims: This study emulated a trial of comparative effectiveness of AHSCT vs. anti-CD20 therapies. Methods: Methods: This cohort\/registry study of comparative treatment effectiveness included data recorded at 7 specialist MS centres with AHSCT programs and international MSBase registry during 2002-2023 (registration nr. ACTRN12605000455662). The study included patients with relapsing-remitting MS, treated with AHSCT or an anti-CD20 monoclonal antibody (ocrelizumab or rituximab), with on-treatment follow-up including \u22652disability assessments. Patients were matched on a propensity score derived from their clinical and demographic characteristics. The matched groups were compared on annualised relapse rates (ARR), freedom from relapses and 6-month confirmed disability worsening and improvement, using a negative binomial model or Cox proportional hazards models, adjusted for paired structure of the matched dataset. Treatment safety was reported in the AHSCT group. <\/p>\n<p>Results: The matching of 152 AHSCT-treated patients and 2572 anti-CD20-treated patients reduced the measured differences between the groups by 99.6%. The matched cohorts had highly active MS (79-82% of patients had experienced relapses in the prior 2 years), mean EDSS exceeding 3.5, and were followed-up for a mean of 4.03 (AHSCT) and 2.37 years (anti-CD20 therapy). 13 patients from the AHSCT group (8.6%)) were previously treated with an anti-CD20 therapy. Compared with anti-CD20 therapy, AHSCT was associated with a lower risk of relapses (mean ARR \u00b1 SD 0.04\u00b10.25 vs. 0.09\u00b10.32, respectively, p&lt;0.0001; number needed to treat 20 patient-years; hazard ratio 0.43, 95% confidence interval [95%CI]=0.26-0.71), similar risk of EDSS worsening (hazard ratio 0.91, 95%CI=0.50-1.66) and higher probability of EDSS improvement (hazard ratio 1.91; 95%CI=1.24-2.96). AHSCT was associated with a risk of infections. No treatment-associated deaths were reported. Conclusion: <\/p>\n<p>Conclusion: Disclosures: Among patients with active relapsing-remitting MS and moderate disability, AHSCT is superior to anti-CD20 therapies ocrelizumab and rituximab at suppressing relapses and enabling recovery of neurological function.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2025\/09\/hsct-is-more-effective-than-anti-cd20-in-the-real-world\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hsct-is-more-effective-than-anti-cd20-in-the-real-world\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet Abit of a NSS momentpeople with this HSCT had few relapses but more inections that anti-CD20. Abstract Number: 1586\/P848 Effectiveness of autologous haematopoietic stem cell transplant in comparison with anti-CD20 therapies in relapsing-remitting multiple sclerosis Tomas Kalincik et al. Introduction: Autologous hematopoietic stem cell transplant (AHSCT) is a potent therapy available to patients with&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-525","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=525"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/525\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}